Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

NovoCure Limited - Ordinary Shares (NQ: NVCR )

27.45 -1.46 (-5.05%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about NovoCure Limited - Ordinary Shares

< Previous 1 2 3 4 5 6 7 Next >
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of NovoCure Limited (NVCR) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of NovoCure Limited (NVCR) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against NovoCure Limited and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NovoCure Limited and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
From Zai Lab Limited
Via GlobeNewswire
LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
From Novocure
Via Business Wire
Novocure Pledges $3 Million to Conquer Cancer®, the ASCO Foundation, to Support Cancer Research and Education
From Novocure
Via Business Wire
Novocure Reports First Quarter 2023 Financial Results
From Novocure
Via Business Wire
Novocure Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Novocure
Via Business Wire
Novocure Announces 27 Presentations, Including Real-World Evidence and Preclinical Research, at American Association for Cancer Research (AACR) Annual Meeting 2023
From Novocure
Via Business Wire
Novocure to Report First Quarter 2023 Financial Results
From Novocure
Via Business Wire
Kristin Stafford Joins Novocure Board of Directors
From Novocure
Via Business Wire
Novocure Announces 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
From Novocure
Via Business Wire
Novocure Announces Reimbursement of Optune® for the Treatment of Newly Diagnosed Glioblastoma in France
From Novocure
Via Business Wire
Novocure Announces Last Patient Enrolled in Pivotal METIS Study of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer
From Novocure
Via Business Wire
Novocure Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
From Novocure
Via Business Wire
Allyson J. Ocean, M.D., Joins Novocure Board of Directors
From Novocure
Via Business Wire
Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer
From Novocure
Via Business Wire
Novocure Announces Organizational Changes to Prepare for Future Growth
From Novocure
Via Business Wire
Novocure Announces Preliminary Full Year and Fourth Quarter 2022 Net Revenues and Provides Company Update
From Novocure
Via Business Wire
Zai Lab and Novocure Announce Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint
From Zai Lab Limited
Via GlobeNewswire
Novocure Announces Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint
From Novocure
Via Business Wire
Novocure to Participate in 41st Annual J.P. Morgan Healthcare Conference
From Novocure
Via Business Wire
Novocure’s Optune® Approved in Canada for the Treatment of Newly Diagnosed and Recurrent Glioblastoma
From Novocure
Via Business Wire
Novocure to Participate in 34th Annual Piper Sandler Healthcare Conference
From Novocure
Via Business Wire
Novocure Announces 25 Abstracts on Tumor Treating Fields Therapy at Society for Neuro-Oncology 2022 Annual Meeting
From Novocure
Via Business Wire
Novocure Opens Office in Montreal to Expand and Support Growing Business in Canada
From Novocure
Via Business Wire
Novocure Secures CE Mark for New Array
From Novocure
Via Business Wire
Novocure Reports Third Quarter 2022 Financial Results
From Novocure
Via Business Wire
Novocure Announces 11 Presentations on Tumor Treating Fields in Multiple Solid Tumor Types at the American Society for Radiation Oncology 2022 Annual Meeting
From Novocure
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.